Milestone Pharmaceuticals Q1 Revenue $238,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Reports Q1 revenue $238,000, consensus $37.64M. "We're excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia, or PSVT. Healthcare professionals' initial reaction to the product is positive and we are very encouraged by the early breadth of unique prescribers writing for their patients," said Joseph Oliveto, President and CEO of Milestone Pharmaceuticals. "Gaining Express Scripts' national formulary coverage in March reflects meaningful early payor adoption, highlighting the value CARDAMYST offers to insurers. We are also observing clinician enthusiasm for expanded development of etripamil in patients with AFib-RVR, as we have now kicked off our Phase 3 pivotal trial and are actively engaging potential clinical trial sites."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIST
Wall Street analysts forecast MIST stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.320
Low
8.00
Averages
8.00
High
8.00
Current: 1.320
Low
8.00
Averages
8.00
High
8.00
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Milestone Pharmaceuticals Grants 288,000 Options to Induce New Hires
- Options Grant Overview: Milestone Pharmaceuticals granted a total of 288,000 options on July 1, 2026, with an exercise price of $1.32 per share, equal to the closing price on the grant date, aimed at attracting six new employees to the company.
- Grant Plan Details: Under the 2021 Inducement Plan, the options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting in 36 equal monthly installments, ensuring employees' continuous service to earn their awards.
- Compliance and Inducement Purpose: This options grant complies with Nasdaq Listing Rule 5635(c)(4) as a material inducement for new hires, aimed at attracting top talent who have not previously worked at Milestone.
- Company Background Information: Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company focused on developing innovative cardiovascular medicines, with its lead product CARDAMYST™ FDA-approved for treating specific heart conditions.
See More
Alpha Cognition Announces Board Changes
- Board Leadership Change: Alpha Cognition has elected Robert Wills as Chairman of the Board, succeeding Len Mertz, who retired after serving since 2021, with Wills' extensive experience expected to provide strategic guidance for the company's future growth.
- Strategic Development Phase: Having served on the Board since 2025, Wills is poised to lead the company through a critical period as it commercializes ZUNVEYL, aiming to advance treatments for neurodegenerative diseases.
- Governance Enhancement: Under Mertz's leadership, Alpha Cognition strengthened its corporate governance framework and achieved several key operational and strategic milestones, with Wills' succession expected to continue this momentum and ensure competitiveness in the industry.
- New Drug Launch: ZUNVEYL, a newly approved treatment for Alzheimer's disease, will benefit from Wills' leadership in driving market adoption and patient acceptance, further solidifying the company's position in the biopharmaceutical sector.
See More
Milestone (MIST) Q1 2026 Earnings Transcript
See More
Milestone Pharmaceuticals Shares Drop 9% Following Disappointing Earnings Report
- Disappointing Earnings Report: Milestone Pharmaceuticals' quarterly earnings report revealed that despite its new drug Cardamyst receiving FDA approval and generating $238,000 in sales during the first quarter, shares fell over 9%, reflecting investor disappointment with the results.
- Surging Commercial Expenses: The company's commercial spending to promote Cardamyst increased by 52% year-over-year, leading to a net loss that deepened to over $26 million ($0.20 per share), compared to a loss of under $20.8 million in the previous year, indicating significant financial pressure from high marketing costs.
- Missed Market Expectations: Analysts had expected Milestone to generate over $56 million in revenue and forecasted a profit of $0.23 per share, but the actual performance fell far short of these expectations, highlighting challenges in the new drug's market penetration.
- Optimistic Future Outlook: Despite the current disappointing performance, Milestone has nearly $184 million in cash and short-term investments, which is expected to sustain operations into the second half of 2027, providing the company ample time to boost Cardamyst's market acceptance and explore additional indications.
See More
Milestone Pharmaceuticals Reports Q1 2026 Earnings with Early Commercial Success
- First Earnings Report: Milestone Pharmaceuticals reported its first earnings for Q1 2026, with CARDAMYST generating $0.2 million in sales, marking the commercial launch for treating acute episodes of paroxysmal supraventricular tachycardia (PSVT), despite being a partial quarter.
- Coverage Improvement: By the end of April, the company captured approximately 600 prescriptions, estimating that 25% of commercially insured patients have quality coverage for CARDAMYST, significantly de-risking the launch and enhancing future sales potential.
- Strong Financial Position: As of March 31, 2026, the company reported approximately $184 million in cash and short-term investments, primarily due to a $75 million cash payment from a royalty purchase agreement with RTW and $19 million in net proceeds, ensuring funding for ongoing product development and market execution.
- Clinical Trial Initiation: The company has initiated the Phase III ReVeRa-301 trial, expecting to enroll its first patient in the second half of 2026, with the study projected to last around two years, targeting 150 to 200 total events, thereby advancing the development of atrial fibrillation treatments.
See More
Milestone Pharmaceuticals Reports Q1 Earnings Miss
- Earnings Miss: Milestone Pharmaceuticals reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.39, indicating significant challenges in profitability that may affect investor confidence.
- Revenue Decline: The company generated only $0.24 million in revenue for the quarter, falling short by $37.4 million, reflecting severe deficiencies in product sales and market demand, which could lead to future cash flow constraints.
- Cash Reserves Increase: As of March 31, 2026, Milestone's cash and short-term investments totaled $184.2 million, a significant rise from $106.0 million on December 31, 2025, indicating improvements in financial management.
- Funding Outlook: The company expects its current cash reserves to cover operating expenses and capital expenditures into the second half of 2027, including costs associated with the upcoming Phase 3 trial in AFib-RVR, demonstrating a commitment to ongoing research and development.
See More
Milestone Pharmaceuticals Grants 288,000 Options to Induce New Hires
- Options Grant Overview: Milestone Pharmaceuticals granted a total of 288,000 options on July 1, 2026, with an exercise price of $1.32 per share, equal to the closing price on the grant date, aimed at attracting six new employees to the company.
- Grant Plan Details: Under the 2021 Inducement Plan, the options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting in 36 equal monthly installments, ensuring employees' continuous service to earn their awards.
- Compliance and Inducement Purpose: This options grant complies with Nasdaq Listing Rule 5635(c)(4) as a material inducement for new hires, aimed at attracting top talent who have not previously worked at Milestone.
- Company Background Information: Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company focused on developing innovative cardiovascular medicines, with its lead product CARDAMYST™ FDA-approved for treating specific heart conditions.
See More
Alpha Cognition Announces Board Changes
- Board Leadership Change: Alpha Cognition has elected Robert Wills as Chairman of the Board, succeeding Len Mertz, who retired after serving since 2021, with Wills' extensive experience expected to provide strategic guidance for the company's future growth.
- Strategic Development Phase: Having served on the Board since 2025, Wills is poised to lead the company through a critical period as it commercializes ZUNVEYL, aiming to advance treatments for neurodegenerative diseases.
- Governance Enhancement: Under Mertz's leadership, Alpha Cognition strengthened its corporate governance framework and achieved several key operational and strategic milestones, with Wills' succession expected to continue this momentum and ensure competitiveness in the industry.
- New Drug Launch: ZUNVEYL, a newly approved treatment for Alzheimer's disease, will benefit from Wills' leadership in driving market adoption and patient acceptance, further solidifying the company's position in the biopharmaceutical sector.
See More
Milestone (MIST) Q1 2026 Earnings Transcript
See More
Milestone Pharmaceuticals Shares Drop 9% Following Disappointing Earnings Report
- Disappointing Earnings Report: Milestone Pharmaceuticals' quarterly earnings report revealed that despite its new drug Cardamyst receiving FDA approval and generating $238,000 in sales during the first quarter, shares fell over 9%, reflecting investor disappointment with the results.
- Surging Commercial Expenses: The company's commercial spending to promote Cardamyst increased by 52% year-over-year, leading to a net loss that deepened to over $26 million ($0.20 per share), compared to a loss of under $20.8 million in the previous year, indicating significant financial pressure from high marketing costs.
- Missed Market Expectations: Analysts had expected Milestone to generate over $56 million in revenue and forecasted a profit of $0.23 per share, but the actual performance fell far short of these expectations, highlighting challenges in the new drug's market penetration.
- Optimistic Future Outlook: Despite the current disappointing performance, Milestone has nearly $184 million in cash and short-term investments, which is expected to sustain operations into the second half of 2027, providing the company ample time to boost Cardamyst's market acceptance and explore additional indications.
See More
Milestone Pharmaceuticals Reports Q1 2026 Earnings with Early Commercial Success
- First Earnings Report: Milestone Pharmaceuticals reported its first earnings for Q1 2026, with CARDAMYST generating $0.2 million in sales, marking the commercial launch for treating acute episodes of paroxysmal supraventricular tachycardia (PSVT), despite being a partial quarter.
- Coverage Improvement: By the end of April, the company captured approximately 600 prescriptions, estimating that 25% of commercially insured patients have quality coverage for CARDAMYST, significantly de-risking the launch and enhancing future sales potential.
- Strong Financial Position: As of March 31, 2026, the company reported approximately $184 million in cash and short-term investments, primarily due to a $75 million cash payment from a royalty purchase agreement with RTW and $19 million in net proceeds, ensuring funding for ongoing product development and market execution.
- Clinical Trial Initiation: The company has initiated the Phase III ReVeRa-301 trial, expecting to enroll its first patient in the second half of 2026, with the study projected to last around two years, targeting 150 to 200 total events, thereby advancing the development of atrial fibrillation treatments.
See More
Milestone Pharmaceuticals Reports Q1 Earnings Miss
- Earnings Miss: Milestone Pharmaceuticals reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.39, indicating significant challenges in profitability that may affect investor confidence.
- Revenue Decline: The company generated only $0.24 million in revenue for the quarter, falling short by $37.4 million, reflecting severe deficiencies in product sales and market demand, which could lead to future cash flow constraints.
- Cash Reserves Increase: As of March 31, 2026, Milestone's cash and short-term investments totaled $184.2 million, a significant rise from $106.0 million on December 31, 2025, indicating improvements in financial management.
- Funding Outlook: The company expects its current cash reserves to cover operating expenses and capital expenditures into the second half of 2027, including costs associated with the upcoming Phase 3 trial in AFib-RVR, demonstrating a commitment to ongoing research and development.
See More
